Application Covid Vaccination

COVID, FDA and vaccines

FDA halts publication of COVID, shingles vaccine studies

News of the studies being pulled comes weeks after the CDC decided it wouldn't publish a report showing last winter's covid vaccine cut the likelihood of hospitalizations.

· 1d

FDA stopped studies supporting COVID-19 and shingles vaccine safety

· 2d

FDA blocked studies finding Covid and shingles vaccines safe, HHS official says

· 22h

‘People should be talking about it’: moves to curtail vaccine information obscures important science, doctors say

A series of high-profile and under-the-radar decisions by US health agencies have scientists and doctors questioning the extent of the agencies’ control over public communications – and they say the d...

· 1d

FDA stopped publication of studies showing COVID, shingles vaccines were safe

· 1d

FDA vaccine studies censored by Trump admin after finding benefits of shots

abc7NY

Pfizer and BioNTech begin application for full FDA approval of their COVID-19 vaccine

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the first Covid-19 vaccine in the United States to be ...

Pfizer asks FDA to approve its experimental antiviral pill for COVID-19

The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes

13d

Europe—not US—first to authorize Moderna’s combo mRNA flu-COVID vaccine

This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s first authorized combination shot for the two respiratory viruses. The decision follows a positive review in February from a key European Medicines Agency’s committee, which paved the way for the approval.

Medscape

First Dual Flu-COVID Vaccine, mCombriax, Wins EU Approval

Combriax demonstrates strong immunogenicity across age groups, exceeding comparator vaccines for multiple influenza strains and SARS-CoV-2 targets.